MEDICLIN AG (MED.DE) Stock Fundamental Analysis
Europe - FRA:MED - DE0006595101 - Common Stock
2.98 EUR
+0.02 (+0.68%)
We assign a fundamental rating of 6 out of 10 to MED. MED was compared to 28 industry peers in the Health Care Providers & Services industry. While MED belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. MED may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
In the past year MED was profitable.
MED had a positive operating cash flow in the past year.
In multiple years MED reported negative net income over the last 5 years.
Each year in the past 5 years MED had a positive operating cash flow.
1.2 Ratios
MED has a Return On Assets of 3.76%. This is in the better half of the industry: MED outperforms 75.00% of its industry peers.
Looking at the Return On Equity, with a value of 14.64%, MED is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
MED has a Return On Invested Capital of 6.72%. This is in the better half of the industry: MED outperforms 78.57% of its industry peers.
MED had an Average Return On Invested Capital over the past 3 years of 3.46%. This is below the industry average of 5.66%.
The 3 year average ROIC (3.46%) for MED is below the current ROIC(6.72%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.76% | ||
| ROE | 14.64% | ||
| ROIC | 6.72% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
MED has a Profit Margin of 4.34%. This is in the better half of the industry: MED outperforms 67.86% of its industry peers.
MED's Profit Margin has improved in the last couple of years.
The Operating Margin of MED (8.17%) is better than 71.43% of its industry peers.
In the last couple of years the Operating Margin of MED has grown nicely.
The Gross Margin of MED (83.90%) is better than 78.57% of its industry peers.
In the last couple of years the Gross Margin of MED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.17% | ||
| PM (TTM) | 4.34% | ||
| GM | 83.9% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
MED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
MED has about the same amout of shares outstanding than it did 1 year ago.
MED has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for MED has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.49, we must say that MED is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MED (1.49) is comparable to the rest of the industry.
The Debt to FCF ratio of MED is 10.50, which is on the high side as it means it would take MED, 10.50 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 10.50, MED perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
MED has a Debt/Equity ratio of 1.84. This is a high value indicating a heavy dependency on external financing.
MED has a Debt to Equity ratio of 1.84. This is in the lower half of the industry: MED underperforms 60.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.84 | ||
| Debt/FCF | 10.5 | ||
| Altman-Z | 1.49 |
ROIC/WACC1.47
WACC4.56%
2.3 Liquidity
MED has a Current Ratio of 1.82. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
MED's Current ratio of 1.82 is amongst the best of the industry. MED outperforms 82.14% of its industry peers.
MED has a Quick Ratio of 1.78. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
MED has a better Quick ratio (1.78) than 89.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
MED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 327.10%, which is quite impressive.
The Earnings Per Share has been growing by 20.79% on average over the past years. This is a very strong growth
Looking at the last year, MED shows a small growth in Revenue. The Revenue has grown by 1.64% in the last year.
The Revenue has been growing slightly by 2.19% on average over the past years.
EPS 1Y (TTM)327.1%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%395.24%
Revenue 1Y (TTM)1.64%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%8.62%
3.2 Future
MED is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.85% yearly.
Based on estimates for the next years, MED will show a small growth in Revenue. The Revenue will grow by 2.80% on average per year.
EPS Next Y52.44%
EPS Next 2Y14.23%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 4.20, the valuation of MED can be described as very cheap.
Based on the Price/Earnings ratio, MED is valued cheaper than 100.00% of the companies in the same industry.
MED's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.41.
With a Price/Forward Earnings ratio of 5.51, the valuation of MED can be described as very cheap.
100.00% of the companies in the same industry are more expensive than MED, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of MED to the average of the S&P500 Index (22.88), we can say MED is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.2 | ||
| Fwd PE | 5.51 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MED indicates a rather cheap valuation: MED is cheaper than 96.43% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, MED is valued cheaper than 85.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.26 | ||
| EV/EBITDA | 2.93 |
4.3 Compensation for Growth
MED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MED has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MED's earnings are expected to grow with 13.85% in the coming years.
PEG (NY)0.08
PEG (5Y)0.2
EPS Next 2Y14.23%
EPS Next 3Y13.85%
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 1.34%.
Compared to an average industry Dividend Yield of 2.57, MED pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.38, MED's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.34% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y14.23%
EPS Next 3Y13.85%
FRA:MED (9/18/2025, 7:00:00 PM)
2.98
+0.02 (+0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners1.7%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap141.55M
Analysts83.33
Price Target4.79 (60.74%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.34% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)26.26%
EPS NY rev (3m)26.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.2 | ||
| Fwd PE | 5.51 | ||
| P/S | 0.18 | ||
| P/FCF | 3.26 | ||
| P/OCF | 1.52 | ||
| P/B | 0.61 | ||
| P/tB | 0.68 | ||
| EV/EBITDA | 2.93 |
EPS(TTM)0.71
EY23.83%
EPS(NY)0.54
Fwd EY18.13%
FCF(TTM)0.91
FCFY30.65%
OCF(TTM)1.96
OCFY65.84%
SpS16.46
BVpS4.88
TBVpS4.37
PEG (NY)0.08
PEG (5Y)0.2
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.76% | ||
| ROE | 14.64% | ||
| ROCE | 8.66% | ||
| ROIC | 6.72% | ||
| ROICexc | 8.86% | ||
| ROICexgc | 9.27% | ||
| OM | 8.17% | ||
| PM (TTM) | 4.34% | ||
| GM | 83.9% | ||
| FCFM | 5.55% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexcg growth 3Y64.29%
ROICexcg growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.84 | ||
| Debt/FCF | 10.5 | ||
| Debt/EBITDA | 3.69 | ||
| Cap/Depr | 96.31% | ||
| Cap/Sales | 6.37% | ||
| Interest Coverage | 2.92 | ||
| Cash Conversion | 80.6% | ||
| Profit Quality | 127.75% | ||
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z | 1.49 |
F-Score8
WACC4.56%
ROIC/WACC1.47
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)327.1%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%395.24%
EPS Next Y52.44%
EPS Next 2Y14.23%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue 1Y (TTM)1.64%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%8.62%
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
EBIT growth 1Y377.48%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year131.21%
EBIT Next 3Y31.07%
EBIT Next 5YN/A
FCF growth 1Y195.08%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.79%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%